Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Terray Therapeutics

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 2

  1. NVIDIA Introduces Nemotron for Science for Scientific Agents

    NVIDIA introduced Nemotron for Science, a package that combines the open Nemotron 3.5 Super VL model, scientific evaluations, the LitmusBench v0.2 chemistry dataset and post-training recipes for domain-specific scientific agents. LitmusBench v0.2 contains nearly 50,000 questions for evaluating and training models on chemistry reasoning, including molecular properties and experimental drug-discovery data. A separate post-training guide describes building a reinforcement-learning environment with NVIDIA NeMo Gym, applying reinforcement learning with NeMo RL and measuring improvement through molecular-similarity scoring. Nemotron 3.5 Super VL and LitmusBench v0.2 are available on Hugging Face, and the model was optimized to run locally on a 128GB NVIDIA DGX Spark.

    NVIDIA Newsroom · 🔥 0
  2. Terray links automated drug labs to an iterative AI discovery loop

    36氪, citing 动脉网, examines Terray Therapeutics’ EMMI platform, which combines high-throughput equipment, automated workflows and AI models so laboratory results can continuously inform model training. Terray and NVIDIA reported fine-tuning Nemotron vision-language models to extract molecular structures, reactants and synthesis routes from reaction diagrams, raising the RxnCaption HybridMatch F1 score from 59.8 to 63.4. The report says this improves chemical-information extraction, but does not demonstrate higher laboratory synthesis efficiency.

    36氪 人工智能 · 🔥 0

Experience and discussion from the community

Share my Terray Therapeutics experienceAsk about Terray Therapeutics

Nobody has shared their experience with Terray Therapeutics yet.